• Poseida Developing CAR T-cells to Replace Risky Stem Cell Transplant Pre-treatments
  • Janssen to Share Updates from Darzalex Studies at Hematology Meeting in Atlanta
  • Bluebird Bio’s CAR T-Cell Therapy Stopped Progression of Hard-to-Treat Myeloma
  • CLR 131 Continues to Show Survival Benefit in Heavily Treated Multiple Myeloma Patients
  • GSK’s Investigational Therapy for Multiple Myeloma Receives Breakthrough Therapy Designation in US
  • Imbruvica OK’d in Canada as Treatment for Chronic Graft-Versus-Host Disease
  • Poseida Awarded $19.8M Grant to Continue Developing P-BCMA-101 for Multiple Myeloma
  • Pomalyst Is More Cost-effective Than Darzalex or Kyprolis for Heavily Treated Myeloma Patients, Study Reports
  • Cellectar Expands Phase 1 Trial to Evaluate Multiple Dosing of CLR 131 in Myeloma Patients
  • Advanced Myeloma Patients Live Longer Before Disease Worsens on Once-weekly Dose of Kyprolis, ARROW Trial Shows
  • British Study Links EZH2 Enzyme to Poorer Myeloma Patient Survival
  • Type of Multiple Myeloma May Affect Responses to Darzalex, Study Finds